Surveys Reveal Oncology Nurses’ CNE Preferences

​At the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California, in April 2019, i3 Health surveyed oncology nurses regarding their educational needs on a variety of topics, including immune checkpoint inhibitors, cyclin dependent kinase (CDK)4/6 inhibitors, chimeric antigen receptor (CAR) T-cell therapy, poly(ADP)-ribose polymerase (PARP) inhibitors, and biosimilars. Regardless of the survey topic, all respondents were asked about their practice role, practice setting, and pre...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Immune Checkpoint Inhibitors

Immune checkpoint inhibition is a form of immunotherapy that blocks checkpoint proteins on immune cells, boosting the body's immune response against cancer cells. Checkpoint inhibitors such as pembrolizumab (Keytruda®, Merck), nivolumab (Opdivo®, Bristol-Myers Squibb), atezolizumab (Tecentriq®, Genentech), durvalumab (Imfinzi®, AstraZeneca), cemiplimab (Libtayo®, Regeneron Pharmaceuticals, Inc.), ipilimumab (Yervoy®, Bristol-Myers Squibb), and avelumab (Bavencio®, EMD Serono and Pfizer) have dem...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Biosimilars

A biosimilar is a biological agent that is very much like another previously FDA-approved biological agent, called the reference drug. Biosimilars and their reference drugs are both made from living organisms, but they may be made in different ways and of slightly different substances. A biosimilar must demonstrate the same safety and efficacy and work in the same way as the reference drug, and it must also be used in the same way, at the same dose, and for the same condition. There are currentl...
Continue reading

Biosimilars in Oncology: An Interview With Eric Zack, DNP, RN, ACNP-BC, AOCN®, BMTCN®

Biosimilars—a biologic that is "similar" to another biologic drug that is already FDA approved—are becoming more common to prescribe to patients with various conditions. It is crucial for health care providers to keep abreast of the current information regarding biosimilars. To help educate oncology nurses on this emerging field, Eric Zack, DNP, RN, ACNP-BC, AOCN®, BMTCN® and colleagues created an intervention including an overview of the history of biosimilars and information about the biosimil...
Continue reading

Aromatherapy for Symptom Management in Patients With Cancer

Nurses at University of Iowa Health Care implemented a quality improvement project that introduced aromatherapy as a nurse-led symptom management intervention intended to increase comfort and reduce symptoms for adult patients with cancer in the outpatient setting. "The poly-pharmacy that occurs with oncology patients can often become overwhelming," stated Jane Utech, MSN, RN, OCN®, and her colleagues Geralyn Quinn, MSN, RN, OCN®, and Michele Farrington, BSN, RN, CPHON, concerning their poster p...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.